

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 03/038051 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number: PCT/US02/34722
- (22) International Filing Date: 31 October 2002 (31.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/000,778 31 October 2001 (31.10.2001) US
- (71) Applicants: **THE METROHEALTH SYSTEM** [US/US]; 2500 MetroHealth Drive, Cleveland, OH 44109-1998 (US). **CASE WESTERN RESERVE UNIVERSITY** [US/US]; 10900 Euclid Avenue, Cleveland, OH 44103 (US).
- (71) Applicants and
- (72) Inventors: **BROWN, Arthur, M.** [US/US]; 9831 Hillsdale Road, Brecksville, OH 44141 (US). **WIBLE, Barbara, A.** [US/US]; 2315 Delaware Drive, Cleveland, OH 44109 (US).
- (74) Agent: **DOCHERTY, Pamela, A.**; Calfee, Halter & Griswold LLP, 1400 McDonald Investment Center, 800 Superior Avenue, Cleveland, OH 44114 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 03/038051 A2**

(54) Title: METHOD OF INDUCING APOPTOSIS IN HYPERPROLIFERATIVE CELLS

(57) Abstract: Methods of inducing apoptosis in hyperproliferative cells, particularly cancer cells are provided. Such method involves increasing the levels of a potassium channel modulatory protein in the cell. Examples of such proteins are native KChAP protein, a biologically active variant of native KChAP protein, or a biologically active KChAP-related protein (collectively referred to hereinafter as "KChAP protein"). In one embodiment, the cells are contacted with the KChAP protein under conditions permitting uptake of the protein by the cells. In another embodiment, the cells are contacted with (i) a nucleic acid encoding the KChAP protein, and (ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the KChAP protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. Methods of detecting cancerous cells in a biological sample selected from the group consisting of a colorectal tissue sample or brain tissue sample are also provided. Such method comprises assaying for the presence of elevated levels of KChAP mRNA or KChAP protein in the sample.

## METHODS OF INDUCING APOPTOSIS IN HYPERPROLIFERATIVE CELLS

This invention was made, at least in part, with government support under National  
5 Institutes of Health Grant No. HL36930, HL55404, HL61642, HL60759, DK54178. The  
U.S. government has certain rights in the invention.

### FIELD OF THE INVENTION

This invention relates to methods of inducing apoptosis in hyperproliferative cells.  
More particularly, this invention relates to methods of inducing apoptosis in cancer cells by  
10 increasing levels of a potassium channel modulatory protein in such cells.

### BACKGROUND

One-third of all individuals in the United States will develop cancer (American  
Cancer Society Yearly Outlook for 1990). Cancer is second only to cardiac disease as a  
cause of death in this country (American Cancer Society Yearly Outlook for 1990).  
15 Currently, cancer therapy employs a variety of procedures including the administration of  
chemicals, chemotherapy, radiation, radiotherapy, and surgery.

Radiotherapy is a regional form of treatment used for the control of localized cancers  
(See Devita, V. T., in Harrison's Principles of Internal Medicine, Braunwald et al., eds.,  
McGraw-Hill Inc., New York, 1987, pp. 431-446). Radiotherapy relies on the fact that some  
20 malignant cells are more susceptible to damage by radiation than normal cells.  
Unfortunately, some tumors cannot be treated with radiotherapy. Moreover, irradiation and  
radioisotope therapy can induce extensive damage of normal tissues.

Surgery is still considered the primary treatment for most early cancers. Although  
most tumors are operable, they not fully resectable. Some tumors that appear resectable have  
25 micrometastatic disease outside the tumor field. This leads to a recurrence of the cancer close  
to the initial site of occurrence.

Cancer chemotherapeutic agents, even though widespread in use, have proved to be of  
limited effect in treating most cancer types. Although there have been some notable successes  
in the treatment of some specific tumor types (e.g., childhood leukemias) with conventional  
30 chemotherapy, more limited success has been obtained in the treatment of solid tumors. This  
failure is primarily due to the low therapeutic index of many anti-cancer drugs, as well as the  
intrinsic or acquired drug resistance that often characterizes tumor cells. Another drawback to

the use of cytotoxic agents for the treatment of cancer is their severe side effects. These include nausea, vomiting, CNS depression, localized pain, bone marrow depression, bleeding, renal damage, hypo and hyperglycemia, and hypersensitivity reactions. Another drawback is that most anti-cancer drugs are only effective against rapidly dividing cells.

5 Cancer can be considered as a disturbed balance between the relative rates of cell proliferation and cell death. Until recently, it was thought that the ultimate result of treatment with anti-cancer drugs was cellular necrosis, a form of cell death that involves a swelling of the cells and membrane rupture. Recently, it has been determined that many anti-cancer drugs induce cell death by apoptosis. Apoptotic cell death is an orderly process which is  
10 typically accompanied by one or more characteristic morphological and biochemical changes in cells, such as condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of the nucleus, degradation of chromosomal DNA or loss of mitochondrial function. A recognized biochemical marker of apoptosis is the cleavage of chromatin into nucleosomal fragments.

15 Certain tumor suppressor proteins, such as p53, have been reported to have a role in inducing apoptosis. Apoptosis is also triggered by the activation of a family of cysteine proteases having specificity for aspartic acid residues. These proteases are designated as caspases (Alnemri, et al., Cell, 87:171, (1996)). One identified substrate for caspase-3 is poly (ADP-ribose) polymerase (PARP).

20 About 50% of human tumors have been shown to have deletions or mutations in the p53 gene and gene product. As a result of this mutation, the cells of these tumors may not be able to undergo apoptosis. This fact may explain the relatively low intrinsic sensitivity of tumors with p53 mutations to conventional chemotherapy.

The need still exists for improved methods for the treatment of most types of cancers.  
25 Additional therapeutic methods for inhibiting or reversing the growth of mammalian tumors, particularly human tumors, are desirable. Methods which induce apoptosis of tumor cells or cancer cells, particularly those methods which induce apoptosis of cancer cells in a p53 independent manner, are especially desirable.

### Summary of the Invention

In one aspect, the present invention provides methods of inducing apoptosis in hyperproliferative cells, particularly cancer cells. Such method involves increasing the levels of a potassium channel modulatory protein in the cell. Examples of such proteins are native KChAP protein, a biologically active variant of native KChAP protein, or a biologically active KChAP-related protein (collectively referred to hereinafter as "KChAP protein"). In one embodiment, the cells are contacted with the KChAP protein under conditions permitting uptake of the protein by the cells. In another embodiment, the cells are contacted with (i) a nucleic acid encoding the KChAP protein, and (ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the KChAP protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. In accordance with the present method, the cancer cells may contain a wild-type or mutant p53 protein. The cancer cells may be in a tissue or cell culture or in a subject. In vivo, the present method can be used to treat a patient with a hyperproliferative disorder, particularly a patient with an epithelial carcinoma, a lymphoma, or leukemia.

In another aspect, the present invention provides a method of inhibiting cell cycling cancer cells that contain a wild-type or native p53 protein. Such method comprises increasing the levels of KChAP protein in such cells.

In another aspect, the present invention provides a method of detecting cancerous cells in a biological sample selected from the group consisting of a colorectal tissue sample or brain tissue sample. In one embodiment, the method comprises contacting the sample or a protein extract therefrom with an antibody to the KChAP protein under conditions wherein antibody binding to one or more epitopes of native KChAP protein occurs; and assaying for the presence or absence of a complex between the antibody and a protein in the sample, wherein an increase in the level of the antigen-antibody complex, as compared to the levels found in a sample of control cells from the same type of tissue, indicates that the sample comprises cancerous cells. In another embodiment, the method comprises assaying for the presence of KChAP transcript in the sample, wherein a increase in the level of the KChAP transcript in the sample, as compared to the level of the transcript in a control sample, denotes that the test sample comprises cancerous cells.

### **Brief Description of the Drawings**

**Figure 1** shows the effect of KChAP overexpression on  $K^+$  loss from prostate cancer cells.

**(A)** Overexpression of KChAP in LNCaP cells for 24 hours results in increased basal  $Rb^+$  efflux compared to control cells overexpressing GFP. Number of 35-mm wells of cells examined is indicated above bars. \* indicates significant difference compared to the control ( $p < 0.005$ ). **(B)** Flow cytometry of LNCaP cells 72 hours after Ad/KChAP infection. In unfixed cells, intracellular  $K^+$  was measured with the  $K^+$  binding dye, PBFI and plotted versus propidium iodide (PI) fluorescence (to distinguish between live and dead cells). Cells in R1 (high PI fluorescence) are classified as dead cells. Most uninfected control cells fall into R3 (low PI, normal  $K^+$ ), while Ad/ KChAP infected cells show a major shift of the population to R2 (low PI, decreased  $K^+$ ). **(C)** Comparison of intracellular  $K^+$  to cell size in control and Ad/ KChAP infected cells. Dead cells in R1 were removed from analysis and those in R2 and R3 were replotted to evaluate  $K^+$  as a function of cell size. Cell size was estimated by forward scatter. Decreased intracellular  $K^+$  in -overexpressing cells correlated with cell shrinkage. A grid was placed over each panel to emphasize the decreased intracellular  $K^+$  seen in -infected cells compared to uninfected cells of the same size.

**Figure 2(A)** shows the effect of KChAP overexpression on apoptosis in prostate cancer cells. Apoptosis in LNCaP cells infected with either Ad/GFP or Ad/ KChAP (m.o.i. of 100; greater than 95% cells infected) was monitored by examining PARP cleavage on Western blots. KChAP, both endogenous and overexpressed, was detected with the antibody (899).

**Figure 2 (B)** shows the effect of staurosporine treatment on KChAP and PARP expression in prostate cancer cells. KChAP (68 kD) immunoreactivity increases in LNCaP and Jurkat T-cells treated with staurosporine (STS, 1  $\mu$ M). Western blot analysis of and PARP expression in lysates of LNCaP and Jurkat cells shows increased reactivity of the 68 kD band with the antibody after treatment with STS. Increased immunoreactivity is maintained until significant PARP cleavage is detected after which the signal drops to below control levels.

**Figure 3** shows the effect of KChAP overexpression on DNA degradation and PARP cleavage in prostate cancer cells.

**(A)** Comet assay to detect DNA degradation in LNCaP cells three days post-infection with Ad/LacZ or Ad/ KChAP (moi = 100). Cells were counted from four separate infections. An example of a field of cells examined for each type of infection is shown in the upper panels. Quantitation of each infection is presented below. An average of 0.8% of Ad/LacZ infected cells were Comet positive compared to an average of 24.4% of Ad/ KChAP infected cells

( $p < 0.001$ ). **(B)** Western blot of overexpressed KChAP (detected with 088 antibody) and PARP cleavage in LNCaP lysates prepared from cells as described in (A). Each lane represents lysate from a separate batch of infected cells.

**Figure 4** shows the effect of KChAP overexpression on p53 levels and p53-serine 15 phosphorylation in prostate cancer cells.

**(A)** Western blot analysis of LNCaP cell lysates prepared three days after infection with Ad/KChAP or Ad/LacZ viruses (moi of 100). Results are shown from triplicate infections. The 088 antibody reacts only with overexpressed, not endogenous, KChAP. Note that KChAP overexpression is correlated with an increase in total p53 levels (detected with the DO1 antibody) as well as phosphorylation of p53 serine 15. STAT3 and STAT1 levels are not changed. Actin is included as a loading control. **(B)** LNCaP cells were infected with Ad/GFP (g) or Ad/ KChAP (k) (m.o.i. = 100) in the presence of standard medium (RPMI/10% FBS) or media in which extracellular  $K^+$  was altered (5, 25 or 50 mM) (see methods for details of media preparation). Lysates were prepared 72 hours post-infection and examined by Western blotting for PARP, overexpressed KChAP (088 antibody), p53-phosphoserine15, total p53 (DO1 antibody), and STAT3. STAT3 serves as the loading control.

**Figure 5** shows the effect of KChAP overexpression on G0/G1 arrest in prostate cancer cells.

**(A)** Western blot analysis of LNCaP lysates infected either with Ad/GFP (G) or Ad/ KChAP (K) at an moi of 100 (g100 and k100, respectively). Cells were harvested either 24, 48 or 72 hours post-infection. Overexpressed KChAP was detected by the 088 antibody, total p53 by the DO-1 monoclonal. Note that the levels of p21, a transcriptional target of p53 and an inducer of G0/G1 arrest are up in KChAP infected cells as early as 24 hours post-infection. G0/G1 arrest is confirmed by the pattern of Rb (retinoblastoma protein) staining as the hypophosphorylated form predominates at this stage. **(B)** Western blot analysis of cyclins confirms the G0/G1 arrest mediated by in LNCaP cells. LNCaP cells infected with Ad/GFP or Ad/ KChAP at two different moi 100:1 (g100 and k100) and 200:1 (g200 and k200) were examined 72 hours post-infection. Rb expression confirmed G0/G1 arrest as seen in panel A. Consistent with this observation, the levels of two mitotic cyclins A and B were significantly decreased while the level of cyclin D3, a protein predominating in G1, was increased.

**Figure 6** is a flow cytometry analysis of the effects of KChAP overexpression on prostate cancer cells.

(A) LNCaP cells infected with Ad/GFP or Ad/ KChAP (both at m.o.i.=100) were fixed in cold 70% ethanol 24 hours (left panel) or 72 hours (right panel) after infection and stained with propidium iodide. Ten thousand cells from each sample were analyzed using FACScan as detailed in Methods. X-axis is propidium iodide intensity, representing DNA content, and the Y-axis is the number of events, representing cell numbers. (B) Histogram of cell cycle distribution. G0/G1, S, and G2-M phases are indicated. The sub-G0/G1 (DAB) population represents apoptotic cells. The data shown are representative of three independent experiments.

**Figure 7** shows the effect of KChAP overexpression on apoptosis in p53 mutant prostate cancer cells. Western blots of lysates prepared 72 hours post-infection from Du145 cells infected with either Ad/GFP or Ad/ KChAP at two different m.o.i., 200 and 400. (g200, g400 and k200, k400, respectively). Overexpressed KChAP was detected with the 088 antibody. The PARP antibody detected both the 116 kD intact protein as well as the 85 kD cleavage product. Steady-state p53 levels were detected with the DO1 monoclonal antibody, and the phosphorylation state of p53-serine 15 was assessed with a specific polyclonal antibody. Actin was included as a loading control.

**Figure 8** shows the effect of Ad/ KChAP on growth of Du145 tumor xenographs in nude mice.

(A) Comparison of average Du145 tumor sizes among three treatment groups: PBS, Ad/GFP, Ad/ KChAP. Du145 cells injected into the flanks of nude mice were allowed to reach a volume of  $\sim 50 \text{ mm}^3$  after which the tumors were injected every 48-72 hours with either PBS, Ad/GFP, or Ad/ KChAP for a total of 9 injections over a 19-day period. By day 7, the tumor volume of Ad/ KChAP injected tumors was significantly less than either PBS or Ad/GFP injected tumors ( $*p < 0.01$ ). There was no significant difference in tumor size between the PBS and Ad/GFP control groups. (B) immunohistochemistry and TUNEL assay in tumor sections from animals sacrificed two days after the last injection (i.e. day 21 after start of treatment). KChAP overexpression was detected in treated tumor sections with the 088 antibody and colorimetric detection (right panels) and corresponding apoptosis was detected with the TUNEL assay (left panels).

**Figure 9** shows the nucleotide sequence (SEQ ID NO. 1) of a cDNA molecule which encodes human KChAP protein and the derived amino sequence (SEQ ID NO. 2) of human KChAP protein.

**Figure 10** is a sequence comparison of the PIAS family of proteins.

- 5 **Figure 11** is a Western blot analysis of KChAP protein levels in cells from a liver cancer cell line (HumI), colorectal cancer tissue(T) and nearby normal tissue (N), and brain tumor tissue (T) 61, 64, 71 and 85) and nearby normal tissue (46, 54, and 86).

### **Detailed Description of the Invention**

Definitions:

- 10 Herein, "apoptosis" is used in a broad sense and refers to the orderly or controlled form of cell death that is typically accompanied by one or more characteristic cell changes, including condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of the nucleus, degradation of chromosomal DNA or loss of mitochondrial function. This activity can be determined and measured, for instance, by cell viability assays, FACS analysis or DNA  
15 electrophoresis, all of which are known in the art. In particular, apoptosis can be measured using the assays described below and in the Examples.

- "Antibody" as used herein refers to a protein molecule that binds to, cross reacts with, or is immunoreactive with a specific antigen or immunogen. The binding reaction between an  
20 antibody and its antigen is specific in that the antibody binds only to an amino acid sequence present within the specific protein (i.e., an epitope). An anti-KChAP antibody means an antibody molecule that binds to one or more epitopes of native KChAP protein.

- "Biological sample" means a sample of mammalian cells. These cells may be part of a tissue  
25 or organ sample obtained, for example, by biopsy, or they may be individual cells, for example, cells grown in tissue culture.

- "Cancer cell" or "cancerous cell" means a cell in or from a carcinoma, lymphoma, sarcoma  
or leukemia.

30

"Prostate cancer" means any of various carcinomas of prostate tissue.



"cDNA" means a DNA prepared using messenger RNA (mRNA) as template. The advantage of using a cDNA, as opposed to genomic DNA or DNA polymerized from a genomic, non- or partially-processed RNA template, is that the cDNA primarily contains coding sequences of the corresponding protein.

5

"Expression" means the production of a protein or a gene transcript (i.e. mRNA) in a cell.

"Hyperproliferative cell" as used herein refers to a cell that exhibits abnormal proliferation. Cancer cells are examples of hyperproliferative cells.

10

"Label" means to incorporate into a compound a substance that is readily detected. Such substances include radioactive substances and fluorescent dyes, for example.

15

"Native" means the nucleic acid of a non-mutated gene or peptide sequence encoded by such a gene as found in a phenotypically normal cell.

"Neoplasia" means the process resulting in the formation and growth of an abnormal tissue that grows by cellular proliferation more rapidly than normal, and continues to grow after the stimuli that initiated the new growth ceases.

20

"Normal cell" means a non-cancerous cell.

"Overexpressing" as used herein means increasing the levels of an intracellular protein to levels above normal.

25

"Proliferation" means growth and reproduction, i.e., division of cells

30

"Tumor" refers to a spontaneous, new growth of tissue in the body that forms an abnormal mass. Tumors are comprised of cells and such cells are known as tumor cells. Tumors and cells derived from tumors can be either benign or malignant. Cells that are malignant have a variety of properties that benign cells and non-tumor cells do not have. Malignant cells

invade, grow and destroy adjacent tissue, metastasize, and usually grow more rapidly than benign tumor cells. "Neoplasm" is essentially synonymous with tumor.

The terms "treating," "treatment," and "therapy" as used herein refer to curative therapy, prophylactic therapy, and preventative therapy.

The present invention provides a method of inducing apoptosis in a hyperproliferative cell, particularly a cancer cell. The method comprises overexpressing a potassium channel modulatory protein, preferably human KChAP protein or a biologically active equivalent thereof, in the hyperproliferative cell. Such method can be used in vitro or in vivo. Thus, the present method can be serve to treat a patient with a hyperproliferative cell disorder. Hyperproliferative cell disorders include cancers; blood vessel proliferative disorders such as restenosis, atherosclerosis, in-stent stenosis, vascular graft restenosis, etc.; fibrotic disorders; psoriasis; inflammatory disorders, e.g. arthritis, etc.; glomerular nephritis; endometriosis; macular degenerative disorders; benign growth disorders such as prostate enlargement and lipomas; and autoimmune disorders. Cancers are of particular interest, including leukemias, lymphomas (Hodgkins and non-Hodgkins), sarcomas, melanomas, adenomas, carcinomas of solid tissue, hypoxic tumors, squamous cell carcinomas of the mouth, throat, larynx, and lung, genitourinary cancers such as cervical and bladder cancer, hematopoietic cancers, head and neck cancers, and nervous system cancers, and benign lesions such as papillomas. The present method is especially useful for treating a patient with an epithelial carcinoma, such as breast cancer or prostate cancer, or a lymphoma, or a leukemia.

The present method is based in part on the discovery that prostate cancer cells comprising wild-type p53 protein and infected with a a non-replicating, recombinant adenovirus containing KChAP cDNA (Ad/KChAP) undergo apoptosis, as assessed by the COMET assay and PARP cleavage, within a period of three days after infection. Ad/KChAP infection increased p53 levels in these prostate cells and increased phosphorylation on p53 residue serine 15, consistent with activation of p53 as a transcription factor. The G1-cell cycle arrest protein p21, was upregulated and infected cells were initially arrested in G1 as assessed by flow cytometry and Western blotting with antibodies to the cell cycle specific proteins, cyclin A, B, and D3, and the retinoblastoma protein Rb.

It has also been determined that p53 is not essential for KChAP-induced apoptosis, as a prostate cancer cell line with mutant p53 also underwent apoptosis when KChAP was

overexpressed in such cells. Accordingly, the present method may be used to induce apoptosis in cells which comprise a mutant p53 gene.

In accordance with the present invention, it has also been determined that overexpression of KChAP suppresses growth of prostate tumor xenografts in nude mice. In accordance, with the present invention, it has also been shown that increasing levels of KChAP protein in MCF-7 cells induces apoptosis in these breast cancer cells. It has also been shown that staurosporine a commonly used inducer of apoptosis causes apoptosis in Jurkat cells, which serve as a model for leukemia, and greatly increases their KChAP content. It has also been determined that hyperproliferative cells such as prostate cancer cells and breast cancer cells are about ten times more sensitive to overexpression of KChAP than non-cancerous cells such as cardiomyocytes.

The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued U.S. patents, allowed applications, and other publications cited herein are hereby incorporated by reference.

#### 15 KChAP Protein

KChAP protein is a potassium channel modulatory protein that interacts with multiple binding partners including Kvs 1.3, 1.4, 1.5, 2.1, 2.2, 4.2 and 4.3; Kv $\beta$  1.2 and Kv $\beta$  2.1; p53; STAT3; SUMO-1; UBC9; HSF-1 (heat shock factor 1) and BRCA1 and 2. The mature form of KChAP has a calculated molecular weight of about 62.4 kDa. In one embodiment the human KChAP protein has the amino acid sequence shown in FIG. 9 (SEQ ID NO:2). In one embodiment the nucleic acid which encodes the human KChAP protein has the nucleotide sequence shown in FIG.9, SEQ ID NO. 1. The term KChAP protein encompasses all naturally occurring proteins that comprise a native sequence. Such native sequence KChAP proteins can be isolated from nature or can be produced by recombinant or synthetic means.

#### 25 KChAP Related Proteins

KChAP is a member of a protein family referred to as the PIAS family. PIAS is the acronym for Protein Inhibitor of Activated STAT. Other members of the PIAS family include PIAS1, PIAS $\alpha$ , PIAS $\beta$  and PIAS $\gamma$ , and PIAS3 $\beta$ . PIAS3 $\beta$  is a related-protein whose amino acid sequence is identical to SEQ ID NO. 1, except that it lacks a 39 amino acid insert that is present at the N-terminus of . PIAS3 $\beta$  has been shown to interact with activated STAT3 and potassium channels. Figure 10 shows the amino acid homology between certain members of this family. With respect to cellular distribution the PIAS proteins are strongly

localized to the nucleus where they appear to act as inhibitors of transcription via interactions with STATs and co-repressors or co-activators of transcription in particular with respect to nuclear receptors such as androgen, estrogen and glucocorticoid receptors. PIAS proteins are also present in the cytoplasm where they exert their effects on K<sup>+</sup> channels and septins. The present apoptosis-inducing method employs PIAS family members that are biologically active. "Biologically active" for the purposes herein means having the ability to induce apoptosis in at least one type of mammalian cell in vivo or ex vivo. In particular, the biologically active KChAP related protein increases K<sup>+</sup> efflux, causes cell shrinkage, and activates caspase 3 to produce PARP cleavage.

#### 10 Variants of KChAP.

The present method also employs biologically active variants of the KChAP protein depicted in Figure 9. The biologically active KChAP variant increases K<sup>+</sup> efflux, causes cell shrinkage, and activates caspase 3 to produce PARP cleavage. In addition, the biologically active KChAP variant has at least about 80% amino acid sequence identity with the protein having the deduced amino acid sequence shown in FIG. 9 (SEQ ID NO:2). Such variants include, for instance, proteins wherein one or more amino acid residues are added or deleted at the N- or C-terminus of the sequence of FIG 9 (SEQ ID NO:2) or one or more amino acid residues within SEQ ID NO. 2 are substituted. Ordinarily, a KChAP variant will have at least about 80% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, and even more preferably at least about 95% amino acid sequence identity with the amino acid sequence of FIG 9 (SEQ ID NO:2). Percent (%) amino acid sequence identity with respect to the sequence herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in SEQ ID NO. 2, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as ALIGN.TM. or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Because of its high amino acid identity with PIAS3 $\beta$  can be classified as both a related protein and a variant.

Preferably, the deletions and additions are located at the amino terminus, the carboxy terminus, or both, of SEQ ID NO. 2. Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.

5 It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index score and a similar hydrophilicity value and still result in a protein with similar biological activity, i.e., still obtain a biological functionally equivalent protein. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by  
10 reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

#### ASSAYS FOR APOPTOSIS

Examples of assays for apoptosis are as follows:

##### **Comet (Single-Cell Gel Electrophoresis) Assay to Detect Damaged DNA**

15 The Comet assay, or single-cell gel electrophoresis assay, is used for rapid detection and quantitation of DNA damage from single cells. The Comet assay is based on the alkaline lysis of labile DNA at sites of damage. Cells are immobilized in a thin agarose matrix on slides and gently lysed. When subjected to electrophoresis, the unwound, relaxed DNA migrates out of the cells. After staining with a nucleic acid stain, cells that have accumulated  
20 DNA damage appear as bright fluorescent comets, with tails of DNA fragmentation or unwinding. In contrast, cells with normal, undamaged DNA appear as round dots, because their intact DNA does not migrate out of the cell.

##### **TUNEL Assay**

When DNA strands are cleaved or nicked by nucleases, a large number of 3'-hydroxyl ends  
25 are exposed. In the TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick end labeling), these ends are labeled with UTP using mammalian terminal deoxynucleotidyl transferase (TdT), which covalently adds labeled nucleotides to the 3'-hydroxyl ends of these DNA fragments in a template-independent fashion. The UTP is then detected using specific probes (e.g., you can incorporate BrdUTP and then use a fluorescent anti-BrdU antibody).  
30 The assay can be used on cells in situ or the cells can be analyzed by flow cytometry.

### **Apoptosis Assays Using Annexin V Conjugates**

The human anticoagulant annexin V is a 35–36 kilodalton,  $\text{Ca}^{2+}$ -dependent phospholipid-binding protein that has a high affinity for phosphatidylserine (PS). In normal viable cells, PS is located on the cytoplasmic surface of the cell membrane. However, in apoptotic cells, PS is translocated from the inner to the outer leaflet of the plasma membrane, where it is associated with lipid "rafts" — regions of the plasma membrane that are insoluble in detergents, high in cholesterol and sphingolipids, that sequester glycosylphosphatidylinositol (GPI)-linked proteins and tyrosine-phosphorylated proteins and that seem to be involved in signal transduction. Annexin V that is conjugated to various detectable molecules (i.e., fluorescent molecules) are reacted with cells thought to be undergoing apoptosis. If PS is located on the outer surface of the plasma membrane, the annexin V conjugate will bind and be detectable.

### **Apoptosis Assays Based on Protease Activity**

Members of the caspase (CED-3/ICE) family of proteases are crucial mediators of the complex biochemical events associated with apoptosis. In particular, caspase-3 (CPP32/apopain), which has a substrate specificity for the amino acid sequence Asp-Glu-Val-Asp (DEVD), cleaves a number of different proteins, including poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase, protein kinase, and actin. Procaspase-3 is released from the mitochondria into the cytoplasm during apoptosis and activated to caspase-3 by an as-yet-unknown enzyme. Assays for caspase comprise addition of substrates for the enzyme that, for example, increase their fluorescence upon cleavage by caspase 3.

#### Methods of Inducing Apoptosis of Cancer Cells In Vitro.

The KChAP polynucleotides and proteins may also be used to induce apoptosis in cancer cells that comprise a native p53 gene or, alternatively, that comprise a mutated or mutant p53 gene. Such cells are derived, for example, from an epithelial carcinoma, such as a mammary carcinoma, or a prostate carcinoma, a lymphoma, or a leukemia. The method involves increasing the levels of KChAP protein in the cancerous cells.

#### Inducing Apoptosis with KChAP Polynucleotides and Oligonucleotides

In one embodiment, polynucleotides comprising (i) a coding sequence for KChAP protein, a biologically active variant of KChAP protein, or a biologically active KChAP - related protein, and (ii) a promoter which permits expression of the protein encoded by the coding sequence are introduced into such cells to permit expression or overexpression of the

respective protein. Polynucleotides comprising sequences encoding a KChAP protein or a biologically active variant thereof may be synthesized in whole or in part using chemical methods. Polynucleotides which encode a KChAP protein, particularly alleles of the genes which encode a native KChAP protein, may be obtained by screening a genomic library or  
5 cDNA library with a probe comprising sequences identical or complementary to the sequences shown in Fig. 9 or with antibodies immunospecific for a protein to identify clones containing such polynucleotide. Variants of the KChAP polynucleotide may be made by site-directed mutagenesis and other methods known in the art.

Viral or plasmid vectors may be used to deliver the KChAP polynucleotide to the cell.  
10 "Vector" as used herein refers to a structure composed of covalently linked nucleotides which is able to enter a cell. Alternatively the KChAP polynucleotide may be incorporated into a liposome which, preferably, further comprises a molecule which targets the liposome to the cancer cell.

#### Viral Vector

15 Examples of known viral vectors are recombinant viruses which are generally based on several virus classes including poxviruses, herpesviruses, adenoviruses, parvoviruses and retroviruses. Such recombinant viruses generally comprise an exogenous gene under control of a promoter which is able to cause expression of the exogenous gene in vector-infected host cells. Recombinant viruses which can be used to transfect cells are mentioned and cited for  
20 example in a review by Mackett, Smith and Moss (1994) J Virol 49(3): 857-864.

Preferably, the virus vector is a defective adenovirus which has the exogenous gene inserted into its genome. The term "defective adenovirus" refers to an adenovirus incapable of autonomously replicating in the target cell. Generally, the genome of the defective adenovirus lacks the sequences necessary for the replication of the virus in the infected cell.  
25 Such sequences are partially or, preferably, completely, removed from the genome. To be able to infect target cells, the defective virus must contain sufficient sequences from the original genome to permit encapsulation of the viral particles during in vitro preparation of the construct.

Preferably, the adenovirus is of a serotype which is not pathogenic for man. Such  
30 serotypes include type 2 and 5 adenoviruses (Ad 2 or Ad 5). In the case of the Ad 5 adenoviruses, the sequences necessary for the replication are the E1A and E1B regions. Methods for preparing adenovirus vectors are described in U.S. Patent No. 5,932,210, which

issued in August, 1999 to Gregory et al., U.S Patent No. 5,985,846 which issued in November, 1999 to Kochanek et al, and U.S. Patent No. 6,033,908 which issued in March, 2000, to Bout et al.

5 More preferably, the virus vector is an immunologically inert adenovirus. As used herein the term "immunologically inert" means the viral vector does not encode viral proteins that activate cellular and humoral host immune responses. Methods for preparing immunologically inert adenoviruses are described in Parks et al., *Proc Natl Acad Sci USA* 1996; 93(24) 13565-70; Leiber, A. et al., *J. Virol.* 1996; 70(12) 8944-60; Hardy s., et al, *J. Virol.* 1997, 71(3): 1842-9; and Morsy et al, *Proc. Natl. Acad. Sci. USA* 1998. 95: 7866-71, 10 all of which are specifically incorporated herein by reference. Such methods involve Cre-*loxP* recombination. In vitro, Cre-*loxP* recombination is particularly adaptable to preparation of recombinant adenovirus and offers a method for removing unwanted viral nucleotide sequences. Replication deficient recombinant adenovirus lacks the E1 coding sequences necessary for viral replication. This function is provided by 293 cells, a human embryonic 15 kidney cell line transformed by adenovirus type. First generation adenoviruses are generated by co-transfecting 293 cells with a helper virus and a shuttle plasmid containing the foreign gene of interest. This results in the packaging of virus that replicates both the foreign gene and numerous viral proteins. More recently, 293 cells expressing Cre recombinase, and helper virus containing essential viral sequences and with a packaging signal flanked by *loxP* 20 sites, have been developed (See Parks et al.) In this system, the helper virus supplies all of the necessary signals for replication and packaging *in trans*, but is not packaged due to excision of essential sequences flanked by *loxP*. When 293-Cre cells are co-transfected with this helper virus, and a shuttle plasmid (pRP1001) containing the packaging signal, nonsense "filler DNA", and the foreign gene, only an adenovirus containing filler DNA and the foreign 25 gene is packaged (LoxAv). This results in a viral recombinant that retains the ability to infect target cells and synthesize the foreign gene, but does not produce viral proteins.

#### Methods for Targeting Cancer cells.

30 Methods for targeting vectors to cancer cells are described in Nakanishi T, Tamai I, Takaki A, Tsuji A. (2000) Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. *Int. J. Cancer.* 88: 274-280, and Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. *J. Mol. Biol.* 301: 1149-1161, both of which are incorporated herein in their



entirety. Methods for delivering isolated oligonucleotides and polynucleotides to cells, including the nucleus of cells, are described in Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. (2000) Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 50: 101-119. Review., and Fisher KD, Ulbrich K, Subr V, Ward CM, Mautner V, 5 Blakey D, Seymour LW. (2000) A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression. Gene. Ther. 7: 1337-1343.

### Liposomes

In another embodiment an expression construct comprising the KChAP 10 polynucleotide may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap 15 water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat (1991) Targeting of liposomes to hepatocytes. Targeted Diagn. Ther 4: 87-103). Also contemplated are lipofectamine-DNA complexes.

### Inducing Apoptosis in Cancer Cells with KChAP Protein and Biologically Active Equivalents Thereof

20 Apoptosis may be induced in cancer cells, particularly prostate cancer cells, by introducing an KChAP protein, or a biologically active KChAP variant, or biologically active KChAP related protein into the cancer cell. A variety of methods exist for introducing proteins and polypeptides into cells. Such methods include, but are not limited to, "protein transduction" or "protein therapy" as described in publications by Nagahara et al. (Nagahara, 25 et al., 1998, Nat Med, 4:1449-52.) and in publications from the laboratory of Dowdy (Nagahara, et al., 1998, Nat Med, 4:1449-52.; Schwarze, et al., 1999, Science, 285:1569-72.; Vocero-Akbani, et al., 2000, Methods Enzymol, 322:508-21; Ho, et al., 2001, Cancer Res, 61:474-7.; Vocero-Akbani, et al., 2001, Methods Enzymol, 332:36-49; Snyder and Dowdy, 2001, Curr Opin Mol Ther, 3:147-52.; Becker-Hapak, et al., 2001, Methods, 24:247-56.), 30 publications which are incorporated herein by reference.

In one embodiment an eleven amino acid sequence, the "protein transduction domain" (PTD), from the human immunodeficiency virus TAT protein (Green and Loewenstein, 1988,

Cell, 55:1179-88.; Frankel and Pabo, 1988, Cell, 55:1189-93.) is fused to the protein. The purified protein is then put in contact with the surface of the tumor cells and the cells take up the protein which functions to inhibit or suppress growth of that cell. In the case where it is desired to introduce the protein containing the fused PTD into cells comprising a tumor in a human or animal, the protein is administered to the human by a variety of methods. Preferably, the protein is administered by intratumoral or intralesional injection.

KChAP proteins that contain the fused PTD are preferably made by fusing the DNA sequence encoding the KChAP protein with the DNA sequence encoding the PTD. The resulting KChAP -PTD fusion gene is preferably incorporated into a vector, for example a plasmid or viral vector, that facilitates introduction of the fusion gene into a organism and expression of the gene at high levels in the organism such that large amounts of the fusion protein are made therein. One such organism in which the vector containing the fusion gene can be expressed is a bacterium, preferably *Escherichia coli*. Other organisms are also commonly used by those skilled in the art. After the fusion protein is expressed at a high level in any of these organisms, the fusion protein is purified from the organism using protein purification techniques well known to those skilled in the art.

#### Methods of Inducing Apoptosis of Cancer Cells In Vivo

In vivo, KChAP protein is overexpressed in cancer cells by administering a pharmaceutical composition comprising a KChAP protein or a polynucleotide encoding a KChAP protein to a subject in need of the same.

In one aspect the method involves administration of the pharmaceutical composition to the patient via local injection. In another aspect, the pharmaceutical composition itself comprises a targeting component which selectively or preferentially targets the pharmaceutical composition to cancer cells. Local injection and targeted delivery, preferably, are used to reduce or avoid introduction of the KChAP protein or KChAP polynucleotide into normal cells.

Those skilled in the art will recognize that delivery via local injection contemplates the use of a syringe, catheter or similar device, which delivers the pharmaceutical composition to the target site, i.e., to an area exhibiting cellular proliferative disease. Delivery may be direct, i.e., intratumoral, or nearly direct, i.e., intralesional, that is, to an area that is sufficiently close to a tumor so that the active agent exhibits the desired pharmacological

activity with respect to the tumor itself. Thus, in one aspect, the pharmaceutical composition is preferably delivered intralesionally or intratumorally.

5 Examples of pharmaceutical compositions which comprise a targeting component include liposomes that comprise not only the KChAP protein or the KChAP polynucleotide but also a targeting molecule, such as for example an antibody that has higher affinity for tumor cells than normal cells. Such liposomes are referred to as immunoliposomes and have the antibody conjugated to the surface the liposome. The liposomes are loaded with the protein or polynucleotide.

10 Another example of such a composition is a recombinant virus which comprises a gene encoding a ligand that specifically binds to a molecule on the surface of the tumor cell. When this virus is grown, the virus-encoded ligand is displayed on the surface of the virus capsid or envelope so it is exposed to the tumor cell that is to be infected. The recombinant virus also encodes the protein.

15 Another example of such a composition is an immunoconjugate in which antibodies or parts thereof are conjugated either to the protein or the polynucleotide. The antibody is chosen to be specific for the tumor cell to which the therapeutic molecule is to be delivered.

Another approach employs a ligand that binds specifically to the tumor cells. Such ligand is conjugated to a therapeutic DNA molecule to be introduced into the tumor cells.

20 Pharmaceutical compositions comprising a targeting component may be administered intravenously or, preferably, intratumorally. The pharmaceutical composition is administered once or repeatedly in a therapeutically effective amount. As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical formulation or method that is sufficient to show a meaningful subject or patient benefit, i.e., a reduction in tumor size, arrest, or inhibition of tumor growth and/or motility or metastasis, and/or an increase in apoptosis, and/or a reduction the symptoms related to the presence of the tumor.

30 The therapeutically effective amount of the KChAP-encoding nucleic acid or KChAP protein in the pharmaceutical composition used in the method of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Preferably, the amount of nucleic acid encoding the KChAP protein is from about 0.001 ng to about 1 mg per kg body weight. Initially, the attending physician will administer low doses of the composition and observe the patient's

response. Larger doses of composition may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to one individual as a single treatment episode. Ultimately, the attending physician will decide the amount of therapeutic composition with which to treat each individual patient.

When a therapeutically effective amount of the pharmaceutical composition used in the method of the invention is administered by injection, the pharmaceutical composition will preferably be in the form of a pyrogen-free, parenterally-acceptable, aqueous solution. The preparation of such parenterally-acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the level of ordinary skill in the art of pharmacology. A preferred pharmaceutical composition for injection should contain, in addition to the vector, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, phosphate buffered saline (PBS), or other vehicle as known in the art. The pharmaceutical composition used in the method of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The duration of therapy with the pharmaceutical composition used in the method of the present invention will vary, depending on the unique characteristics of the pharmaceutical composition and the particular therapeutic effect to be achieved, the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending physician will decide on the appropriate duration of therapy with the pharmaceutical composition used in the method of the present invention.

#### Methods of Detecting Cancer Cells in Colon, Rectal, and Brain Tissue Samples

##### A. Methods That Employ Anti-KChAP Anti- Antibodies

In accordance with the present invention, it has been determined that colorectal cancer cells and brain cancer cells have higher intracellular levels of KChAP protein than normal cells obtained from the same type of tissue. Accordingly antibodies immunospecific for KChAP protein are useful diagnostic markers for detecting cancerous cells in a colon tissue sample, rectal tissue sample, or brain tissue sample. The diagnostic method comprises the steps of contacting a sample of test cells or a protein extract thereof with immunospecific anti- KChAP antibodies and assaying for the formation of a complex

between the antibodies and a protein in the sample. The cells may be fixed or permeabilized to permit interaction between the antibody and intracellular proteins. Interactions between antibodies and a protein or peptide in the sample are detected by radiometric, colorimetric, or fluorometric means. Detection of the antigen-antibody complex may be accomplished by  
5 addition of a secondary antibody that is coupled to a detectable tag, such as for example, an enzyme, fluorophore, or chromophore. Formation of higher levels of complex in the test cell as compared to the normal cells indicates that the test cell is cancerous.

The sample may be untreated, or subjected to precipitation; fractionation, separation, or purification before combining with the anti- KChAP protein antibody. In those cases  
10 where proteins are extracted from the sample, it is preferred that isolated proteins from the sample be attached to a substrate such as a column, plastic dish, matrix, or membrane, preferably nitrocellulose. For isolated protein, the preferred detection method employs an enzyme-linked immunosorbent assay (ELISA) or a Western immunoblot procedure.

Formation of the complex is indicative of the presence of the KChAP protein in the  
15 test sample. Thus, the method is used to determine whether there is a decrease or increase in the levels of the KChAP protein in a test sample as compared to levels of the protein in a control sample and, optionally, to quantify the amount of the KChAP protein in the test sample. Deviation between control and test values establishes the parameters for diagnosing the disease. It is contemplated that the levels of KChAP protein in cancerous cells will be at  
20 least 50% greater than the level of protein in non-cancerous cells.

#### B. Methods That Employ KChAP Polynucleotides and Oligonucleotides

Alternatively, KChAP polynucleotides or fragments thereof may be used to detect or define the borders of, colorectal cancers or brain cancers in patients known to have or suspected of having said cancer. The KChAP polynucleotides may be used as probes in  
25 Northern analysis to identify tissues which have comparatively higher levels of mRNA. In such procedures total RNA or mRNA is obtained from the cells that are known to be or suspected of being cancerous and from non-cancerous cells, e.g. prostate epithelial cells, preferably from the same patient, and then assayed using the KChAP-designed probe. In general, the non-cancerous cells will be obtained from tissues near but outside the border of  
30 the expected carcinoma.

In one example, the coding sequence is radioactively labeled with  $^{32}\text{P}$  or digoxigenin, and then hybridized in solution to RNA that is isolated from test cells, e.g., mammary epithelial cells suspected of being cancerous, and separated by size using gel electrophoresis and blotted to nitrocellulose paper. After hybridization and washing of the nitrocellulose paper, hybridization of the probe to RNA on the nitrocellulose, as revealed by autoradiography, indicates expression of the mRNA. Increased levels of KChAP mRNA expression in the test cells as compared to levels of KChAP mRNA present in normal epithelial cells derived from the same type of tissue indicates that the test cells are cancerous.

In another embodiment of the present invention, KChAP probes, labeled as described above, are used to hybridize directly to test cells, e.g. prostate epithelial cells or tissues suspected of being cancerous, and to normal cells derived from the same type of tissue, i.e. control cells. The cells or tissues are fixed before hybridization, using procedures well known to those skilled in the art. Hybridization is performed under conditions similar to those described above. Detection of hybridization, by autoradiography for example, indicates the presence of KChAP transcripts within the cells or tissues. An increase level of KChAP transcripts in the test tissues or cells as compared to control cells indicates that the test cells are cancerous.

Similarly, KChAP -designed primers may be used in RT-PCR to quantify the amount of mRNA in the test tissues and cells. Alternatively, KChAP -designed primers may be used to analyze tissue sections from human patients by an RT in situ-PCR hybridization protocol as described Nuovo et al (1994) in Am J. Pathol., 144, 659-666, which is specifically incorporated herein by reference.

The invention may be better understood by reference to the following examples, which serve to illustrate but not to limit the present invention.

## EXAMPLES

### METHODS

Cell Culture and Adenovirus infection LNCaP, Du145, and Jurkat cells were obtained from the American Type Culture collection. LNCaP cells is a prostate cancer cell line in which the cancer cells contain native p53 protein. Du145 is a prostate cancer cell line in which the cancer cells contain mutated p53 protein. Jurkat cells serve as a model system for leukemia. LNCaP and Jurkat cells were maintained in RPMI medium with 10% FBS, while Du145 cells

were propagated in DMEM medium plus 10% FBS. All media also contained 100 units/ml penicillin and 100 µg/ml streptomycin.

A replication-defective, recombinant KChAP /adenovirus was constructed as follows. Full-length KChAP cDNA was subcloned in the vector, pShuttle-CMV, and sent to Q-Biogene for adenovirus construction and purification. Expression of from the recombinant adenovirus, Ad/ KChAP, was verified by Western blotting lysates of infected cells with a specific antibody, 088, which recognizes only overexpressed (see details below). Recombinant Ad/GFP and Ad/LacZ were purchased from Q-Biogene. Viral infections were performed by diluting the virus to the appropriate concentration in standard medium and overlaying the cells (1 ml/35 mm dish). The media was not changed until the cells were harvested.

*Antibodies and Western Blotting* Two antibodies were used to monitor intracellular levels of KChAP protein in control and Ad/KChAP infected cells. Antibody 899 was raised against a bacterial fusion protein which consisted of the C-terminal 169 amino acids of KChAP ( Wible et al, 1998; Kuryshev et al 2000). It recognizes both endogenous and overexpressed KChAP. Antibody 088 was raised against a peptide in the N-terminus of KChAP which is not present in PIAS3 (SPSPLASIPPTLLTPGTLL-GPKREVDMH, SEQ ID NO. 3). Antibody 088 recognizes only overexpressed, not endogenous, KChAP . Affinity purified antibodies were used in Western blotting. Other antibodies used for Western blotting to detect the following proteins were obtained from commercial sources: p53 (DO-1; Santa Cruz Biotech.), STAT1, STAT3, and cyclins A, B, and D3 (Transduction Labs), actin (clone AC-40, Sigma), phospho-p53 (ser 15) (Cell Signaling Tech. Inc.), PARP (we used two antibodies interchangeably which recognize both intact and cleaved PARP; one from Cell Signaling Inc., and one from Pharmingen), monoclonal Rb (Pharmingen), and p21 (WAF1 Ab1; Oncogene Res. Pds).

Cells were lysed in a buffer consisting of 1% Triton-X 100, 150 mM NaCl, 50 mM Tris, 1 mM EDTA, pH 7.5 containing freshly added protease inhibitors (Complete, Roche Mol. Biol.) and the phosphatase inhibitors sodium fluoride (50 mM) and sodium orthovanadate (1 mM) for 30 minutes on ice. Insoluble debris was pelleted at 20,800 x g for 10 minutes at 4°C. Lysate protein concentrations were determined by the BCA method (Pierce), and aliquots were boiled in a reducing SDS sample buffer to denature protein. SDS PAGE gels were blotted to PVDF membranes using a semi-dry blotting apparatus. Blots were blocked overnight in 5% milk (Bio-Rad) in PBS-T (PBS plus 0.1% Tween-20) at 4°C.

Primary antibodies diluted in blocking buffer were incubated with the blots for one hour at room temperature (RT). Blots were washed with PBS-T and incubated with HRP (horseradish peroxidase)-conjugated secondary antibodies (Amersham Pharmacia) in blocking buffer for 1 hour at RT. Blots were developed with the ECL-Plus kit (Amersham Pharmacia).

*COMET Assay* DNA degradation was assayed in cells overexpressing Ad/ KChAP or Ad/LacZ using the kit from Trevigen.

*Rb<sup>+</sup> flux* LNCaP cells were plated in 6-well tissue culture dishes at 250,000 cells per well. On the following day, cells were infected with either Ad/GFP or Ad/ KChAP (m.o.i. = 100).

*Rb<sup>+</sup> fluxes* were measured 24 hours after infection using the non-radioactive method of Terstappen (Terstappen, 1999). To load Rb<sup>+</sup>, cells were incubated for 4 hours (37 °C) in a modified Tyrode's solution containing (in mM): 5 RbCl, 145 NaCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 10 glucose (pH 7.4 at 37 °C) and 10% FBS. The cells were then washed 3 times with Rb<sup>+</sup> free-PBS and incubated for 10 minutes at room temperature in 1 ml of normal Tyrode's solution. The supernatant containing released Rb<sup>+</sup> was collected and the cells were lysed in 1 ml PBS containing 1% Triton X-100 to measure Rb<sup>+</sup> remaining in the cells. Samples were diluted (1:4) with ionization buffer (PBS containing 2.5% HNO<sub>3</sub>) and Rb<sup>+</sup> content was determined using flame atomic absorption spectrophotometry at 780 nm (Perkin-Elmer 3100). A calibration curve was constructed to determine Rb<sup>+</sup> concentrations. Relative Rb<sup>+</sup> efflux was calculated as the amount of Rb<sup>+</sup> in the supernatant divided by total Rb<sup>+</sup> (supernatant plus cell lysate).

*Flow cytometric analysis. Potassium (K<sup>+</sup>) content* At 72 hours post-infection with either Ad/GFP or Ad// KChAP (m.o.i. = 100), LNCaP cells were collected by trypsin treatment and washed in PBS. The K<sup>+</sup> sensitive dye, potassium-binding benzofuran isophthalate (PBFI), (Molecular Probes) was dissolved in Pluronic F-127 (Molecular Probes), and incubated with the cells in standard medium at a final concentration of 5 μM for 1 hour at 37°C. The cells were then chilled on ice and propidium iodide (5ug/ml) was added. Flow cytometry was performed with a Becton Dickinson FACS Vantage machine. Ten thousand cells from each treatment group were analyzed. Excitation of PBFI was at 340 nm and emission captured at 425 nm. Propidium iodide was excited by a 488 nm argon laser at the same time.

*DNA content* For DNA content analysis, cells were trypsinized either 24 or 72 hours post-infection as described above, washed with PBS, and fixed in cold 70% ethanol for at least 8



hours at  $-20^{\circ}\text{C}$ . After washing in PBS, propidium iodide ( $5\ \mu\text{g}/\text{ml}$ ) was added. Ten thousand cells were examined by flow cytometry for each sample using a Becton Dickinson FACScan (excitation at  $488\ \text{nm}$ ).

*Tumor production and adenovirus injection in nude mice* Tumor cells (Du145 or LNCaP;  $2 \times 10^6$  cells per injection site) were suspended in serum free DMEM, mixed with an equal volume of cold Matrigel on ice, and injected subcutaneously into both flanks of 8-9 week old female Balb/c nude mice. Tumor growth was monitored using calipers every 2 to 3 days. Tumor volume was calculated as  $(L \times W^2)/2$ , where L is length and W is width in millimeters. When tumors reached an average size of  $50\text{-}60\ \text{mm}^3$  (about 2 weeks for Du145 and 5 weeks for LNCaP), mice were divided into three treatment groups: (1) PBS, (2) Ad/GFP, and (3) Ad/KChAP. Both tumors on an individual mouse received the same treatment. Ad/GFP and Ad/KChAP were diluted in sterile PBS to  $5 \times 10^8$  pfu/ $\mu\text{l}$ . Injections ( $1\ \mu\text{l}/\text{mm}^3$  of tumor) were delivered directly into the tumors every 2 to 3 days for a total of 3 injections per week.. Assuming  $10^6$  cells per  $\text{mm}^3$  of tumor, about 500 pfu of virus per tumor cell was injected at 48-72 hour intervals. Mice were sacrificed by cervical dislocation 48 hours after the final injection, and tumors were dissected and frozen in liquid nitrogen. During the experiments, the animals were housed and handled in accordance with the National Institutes of Health guidelines.

*Immunohistochemistry and TUNEL assay of tumor sections* Eight-micron sections were prepared from frozen tumors dissected from the three treatment groups (PBS, Ad/GFP, and Ad/KChAP), mounted, and fixed on glass slides. Overexpressed was detected by incubating sections with the 088 antibody (1:100 dilution in 0.2% gelatin/0.5% BSA/PBS) for two hours at room temperature (RT), washing with PBS, and incubating with biotinylated anti-rabbit secondary antibody (1:200) for one hour at RT. Color development was done with the ABC and DAB kits from Vector labs following their instructions. Apoptosis of cells in tumors subjected to different treatments was determined by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) assays using the Apo-Tag kit (Oncor, Inc.), following the manufacturer's instructions.

EXAMPLE 1 : KChAP Overexpression of in Prostate Cancer Cells*KChAP increases  $K^+$  efflux in LNCaP cells*

To examine the effect of increased intracellular levels of KChAP on  $K^+$  flux, LNCaP cells were infected with either Ad/GFP or Ad/KChAP (moi of 100) for 24 hours after which they were loaded with the potassium surrogate rubidium ( $Rb^+$ ) and assayed for  $Rb^+$  release by flame atomic absorption spectroscopy. LNCaP are a model cell line for prostate cancer cells which comprise native or wild-type p53 protein. As shown in Figure 1A, KChAP -overexpressing cells showed a significant increase (about 20%) in the fraction of  $Rb^+$  released compared to cells infected with a GFP virus. In a 10 minute period, about 12.5% of the loaded  $Rb^+$  was released from Ad/GFP infected cells whereas over 15% was released from cells infected with Ad/KChAP.

The relative amount of  $K^+$  in Ad/KChAP -infected cells was measured at later times after infection using flow cytometry with the potassium sensitive dye, PBFI. LNCaP cells were harvested 72 hours post-infection with Ad/KChAP (m.o.i =100). Uninfected cells were used for comparison as the expression of GFP would have interfered with the detection of the dye. In Figure 1B, the amount of PBFI fluorescence reflecting intracellular  $K^+$  was plotted against propidium iodide (PI) fluorescence. Cells with high PI intensity (R1 section) were dead cells and thus not analyzed further. In cells with low PI fluorescence (live cells, sections R2 and R3), there was a clear shift of the population to lower intracellular  $K^+$  levels. As we are measuring total  $K^+$  and not  $K^+$  concentration, this decrease in  $K^+$  may reflect cell shrinkage. When the cells in R2 and R3 were replotted to examine cell size (reflected in the forward scatter values collected from the flow cytometer) versus intracellular  $K^+$  (Figure 1C), we find that this is the case. In KChAP -infected cells there was a dramatic decrease in average cell size which paralleled the decrease in intracellular  $K^+$ . Thus, / KChAP stimulated release of  $K^+$  from cells when measured 24 hours after introduction of the AD/KChAP virus, and produced a significant decrease in cell size when assessed 72 hours post-infection. From the data in Figure 1C, it also appeared that the concentration of  $K^+$  was decreased in apoptotic, Ad/ KChAP infected cells. For example, the smallest uninfected cells fell into the sector b3 (<400 cell size units), while the majority of the smallest -infected cells fell into sector b4.

*KChAP sensitizes cells to apoptotic stimuli*

LNCaP cells two days post-infection (moi of 100) with either Ad/GFP or Ad/ KChAP were treated with the apoptotic stimulus staurosporine (STS), lysed, and apoptosis assessed by PARP cleavage on Western blots. Staurosporine (STS) was from Sigma and a 1 mM stock solution was prepared in DMSO and stored at -20°C. A final concentration of 1 μM was used to induce apoptosis. As shown in Figure 2A, no PARP cleavage was detected in cells overexpressing either GFP or KChAP two days after infection. PARP cleavage was detected as early as two hours after the addition of STS (1 μM) in KChAP expressing cells and was about 50% complete at 6 hours. This is in contrast to GFP expressing cells in which PARP cleavage was not detectable at all until 6 hours of STS treatment. KChAP expression was examined with the 899 antibody which detects both endogenous and overexpressed KChAP. Overexpressed KChAP migrates at the same position as the endogenous 68 kD doublet and largely disappears as PARP cleavage progresses. Thus, KChAP makes LNCaP cells more sensitive to STS-induced apoptosis.

We observed an increase in the amount of endogenous KChAP detected in cells exposed to STS. Figure 2B shows Western blots of endogenous KChAP from both LNCaP and Jurkat cells treated for various lengths of time with 1 μM STS. Multiple bands are detected in both cell lysates with the 899 antibody; a 68 kD doublet which is close to the predicted molecular weight of KChAP and PIAS3 and an upper band of about 85 kD. Figure 2B shows that the signal of the 68 kD doublet obtained with the 899 antibody is increased as early as one hour after the addition of STS. The signal then drops to control levels or lower after about 6 hours in LNCaP cells and around 4 to 6 hours in Jurkat cells. This peak in immunoreactivity largely precedes detection of PARP cleavage, a marker for apoptosis. Once significant PARP cleavage is detected, much less KChAP is detected by Western blotting. There was no change in the 85 kD band. This phenomenon is not limited to STS as the same pattern was also obtained with the apoptotic inducing drug camptothecin (data not shown). Whether the increased signal on Western blots is due to increased KChAP protein levels or posttranslational modification of the protein to make antibody binding more accessible is not yet known. However, this pattern is consistent with a proapoptotic protein that is upregulated or activated early after the apoptotic stimulus.

*KChAP alone induces apoptosis in LNCaP cells*

We saw no PARP cleavage in Ad/ KChAP infected LNCaP cells at two days post-infection in the absence of STS. When infected LNCaP cultures were examined microscopically at later times after infection, however, we observed that many of the cells  
5 had become detached from the culture dish consistent with cell death. To determine if KChAP overexpression alone is sufficient to induce apoptosis, we assayed for apoptosis in cells three days after infection using the Comet assay to detect DNA degradation. Control infections were done with Ad/LacZ to prevent interference of GFP with the Comet assay.

Figure 3 shows the results of four independent infections. The top panel shows a  
10 typical field of nuclei assayed from cells infected with Ad/LacZ (left) or Ad/ KChAP (right). Quantitation of the number of Comet positive cells is presented in the table below. A substantial increase (about 25-fold) in the number of cells with degraded DNA is observed in cells overexpressing KChAP compared to LacZ (an average of 24.4% comet positive versus 0.8%, respectively).

15 In addition to the Comet assay, we also examined PARP cleavage in cells three days post-infection (Figure 3, bottom panel). Lysates from LNCaP cells infected with either Ad/LacZ or Ad/ KChAP at an moi of 100 were probed with anti-PARP antibody on Western blots. Lysates from three different batches of infected cells showed detectable PARP cleavage coincident with the expression of KChAP. The antibody 088 which only detects  
20 overexpressed KChAP was used to verify AD/ KChAP viral infection. Thus, overexpression of KChAP is able to trigger apoptosis in LNCaP cells with both DNA degradation and PARP cleavage apparent three days after infection.

*KChAP overexpression increases p53 levels and p53-serine15 phosphorylation*

p53, a tumor suppressor protein mutated in about 50% of all human cancers, is able to  
25 induce apoptosis as well as produce cell cycle (G0/G1) arrest. In yeast two-hybrid experiments, we have found that KChAP is able to interact with p53 (unpublished observations). LNCaP cells have wild-type p53, and low endogenous levels are maintained through a complex set of regulatory mechanisms. Since wild-type p53 can produce apoptosis in many cell types, we examined AD/GFP and Ad/ KChAP infected LNCaP lysates for p53  
30 levels. Western blotting with the DO1 antibody showed an increased amount of total p53 protein in KChAP overexpressing cells three days post-infection (Figure 4A). The increased p53 levels were coincident with an increase in the reactivity of an antibody specific for p53

phosphorylated on serine 15. We also examined the level of STAT proteins as several members of the PIAS family have been shown to interact with STATs. No changes were detected in either STAT1 or STAT3 levels. These observations suggest that part of the proapoptotic effects of KChAP may be exerted through the upregulation and activation of p53.

To determine if  $K^+$  loss is required for KChAP -mediated p53 activation and apoptosis,  $K^+$  efflux was blocked by incubating cells in media with high extracellular  $K^+$ . Cells were infected with Ad/GFP or Ad/ KChAP in standard medium or medium with increasing concentrations of  $K^+$  (from 5 to 50) and maintained for 72 hours prior to lysis. In these studies, RPMI medium was assembled from the individual components as outlined by Life Technologies Inc. so that we could adjust the  $[K^+]$ . The total amount of  $K^+$  plus  $Na^+$  in the media was kept constant at 150 mM so that when  $[K^+]$  was elevated,  $Na^+$  was correspondingly decreased. Figure 4B shows that apoptosis, detected by PARP cleavage, is largely blocked in cells bathed in 50 mM  $K^+$ . There is a small, basal level of PARP cleavage apparent in GFP-expressing cells in 50 mM  $K^+$  which is not accentuated in KChAP expressing cells. Even though KChAP -induced apoptosis is blocked in high extracellular  $K^+$ , phosphorylation of 53 on serine 15 still occurs. Therefore,  $K^+$  efflux is not required for p53 activation.

#### *KChAP produces G0/G1 cell cycle arrest*

When p53 is activated as a transcription factor, one of its major targets is the cell cycle arrest protein, p21. Increased p21 expression has been linked to cell cycle arrest at G0/G1. We examined the expression of p21 in Ad/ KChAP infected LNCaP cells harvested 24, 48, and 72 hours post-infection. As shown in Figure 5A, a dramatic increase in p21 levels was detected by Western blotting as early as 24 hours post-infection. This increased expression was maintained at 48 and 72 hours after infection, and was coincident with elevated p53 levels observed at 24, 48, and 72 hours in KChAP overexpressing cells. Since elevated p21 would be expected to produce G0/G1 arrest, we examined the expression of a cell cycle marker protein, retinoblastoma (Rb). Rb exhibits cell cycle specific phosphorylation (refs): in G0/G1 cells, Rb is hypophosphorylated and migrates more rapidly on SDS PAGE providing a useful marker for cell cycle arrest. In GFP expressing cells, two forms of Rb are detected: an upper, hyperphosphorylated form and a lower, hypophosphorylated form (Figure 5A). In KChAP expressing cells, only the lower, hypophosphorylated form is detected. This is seen

as early as 24 hours post-infection and is maintained throughout the assay period. In Figure 5B, we examined the expression of several other cyclins as cell cycle markers. Cyclin A and B are mitotic cyclins whose levels decrease during G0/G1 (refs). In -infected LNCaP cells, the levels of both cyclins A and B fall dramatically consistent with G0/G1 arrest. Conversely, a cyclin upregulated during G1 (cyclin D3) is expressed at higher levels in KChAP overexpressing cells. Thus, Western blotting of KChAP-infected cell lysates with cell cycle markers indicates that, in addition to apoptosis, KChAP produces cell cycle arrest at G0/G1.

Cell cycle arrest and apoptosis induced by KChAP were also examined by flow cytometry of infected cells. Ad/GFP and Ad/ KChAP infected cells were fixed either 24 or 72 hours after infection and DNA content assessed by propidium iodide staining. Cells were classified as either DAB (subdiploid), G0/G1 (diploid), S (intermediate), or G2/M (tetraploid). Comparison of the distribution of LNCaP cells after GFP versus KChAP overexpression for 24 hours showed an increase in the population of G0/G1 cells and a decrease in the number of S phase cells among the KChAP infected group (Figure 6A, left panels). A decrease in the number of S phase cells is consistent with G0/G1 arrest as cells are able to exit S phase but no cells are able to enter from G0/G1. The data are plotted in Figure 6B (left panel) as the percentage of cells in each population. The percentage of cells in G0/G1 increases from 62% in GFP expressing cells to 78% in KChAP overexpressing cells, while the S phase population drops from 18% in GFP-cells to 1% in KChAP -cells. When assayed 72 hours after infection, there is a dramatic increase in the number of DAB cells in the KChAP expressing group (5% in GFP cells and 20% in KChAP cells; figure 6A and B, right panels). This group of cells with subdiploid DNA content would consist of apoptotic cells with fragmented DNA. Taken together, these data reflect the temporal pattern of the effects of KChAP on LNCaP cells. An early event (within 24 hours after introduction of cDNA) is the arrest of cells in G0/G1. The by induction of apoptosis is detected 72 hours after Ad/ KChAP infection.

#### EXAMPLE 2: Inducing Apoptosis in Prostate Cancer Cells Comprising a Mutated p53 Protein by Increasing Intracellular Levels of KChAP.

To determine whether wild-type p53 is essential for KChAP effects, we tested the effects of in a cell line with mutant p53. The prostate cancer cell line, Du145, has p53 with several point mutations rendering it nonfunctional as a transcription factor (ref). Du145 cells were infected with Ad/GFP or Ad/ KChAP at two different m.o.i. (200 and 400) and lysates

prepared 72 hours after infection. Greater than 95% of the cells were infected in these experiments as determined by GFP fluorescence and most of the infected cells were floating by day 3 (data not shown). Western blotting shows significant PARP cleavage in Du145 cells infected with Ad/ KChAP compared to control, Ad/GFP infected cells (Figure 7). Steady-state p53 levels are already high in Du145 cells as is often seen when p53 is mutated, and those levels do not increase with KChAP overexpression. The phosphorylation of p53 on serine 15 is still increased in KChAP overexpressing cells, however. Unlike LNCaP cells, there was no upregulation of p21 evident from Western blots in KChAP -overexpressing Du145 cells (data not shown) suggesting that p53 is not an active transcription factor in Du145 cells. Furthermore, flow cytometry of infected Du145 cells showed that the G0/G1 arrest that was apparent in KChAP -overexpressing LNCaP cells was absent from Du145 cells (data not shown). Taken together, these results suggest that wild-type p53 may be involved in -mediated G0/G1 arrest but is not required for KChAP-induced apoptosis.

EXAMPLE 3. Inhibiting In Vivo Growth of Subcutaneous Implants of Human Prostate Cancer Cells by Increasing Intracellular Levels of KChAP

We have shown that KChAP is a potent inducer of apoptosis in cell lines with diverse p53 status. To assess its potential usefulness as an anticancer agent, we created subcutaneous tumors in nude mice by injecting either Du145 or LNCaP cells into the flank area. Du145 cells, mixed with matrigel, formed well established tumors in the flanks of nude mice in about two weeks. Once tumors were established, Ad/ KChAP was injected directly into the tumors every 48-72 hours for a total of 9 injections over a period of 19 days. Two batches of control tumors were injected with either PBS or Ad/GFP. As shown in Figure 8A, injection of Ad/ KChAP significantly suppressed the growth of Du145 tumors compared with Ad/GFP or PBS treatments. In the animals treated with Ad/ KChAP, the mean tumor volume was 81 mm<sup>3</sup> after 19 days (n=8). In contrast, the mean tumor volume reached 492 mm<sup>3</sup> in the Ad/GFP treated group (n=8) and 716 mm<sup>3</sup> in the PBS injected controls (n=10). At the conclusion of the treatment period, mice in the Ad/ KChAP treated group were active and appeared normal in contrast to the mice in the other two groups which had difficulty moving because of the tumor burden and appeared ill.

Tumors from each of the three treatment groups were harvested two days after the last injection and processed for immunohistochemistry. When dissected, Ad/KChAP treated tumors were all localized subcutaneously with clear boundaries, while most tumors from the

two control groups were found to penetrate into adjacent tissues and organs and had a well established blood supply. Sections were stained with antibody 088 to detect overexpressed KChAP, and parallel sections were assayed for TUNEL positive cells (i.e. apoptotic cells with fragmented DNA). Staining with the 088 antibody was seen in many cells from tumors injected with Ad/ KChAP with very little background staining in tumors treated with either Ad/GFP or PBS (Figure 8B, right panels). We have seen previously that the 088 antibody does not stain either Du145 or LNCaP cells in culture (unpublished observations). Overexpression of KChAP was accompanied by apoptosis in the infected tumor cells as the comparison of TUNEL positive cells from each of the three treatment groups showed (Figure 8B, left panels). A low background level of TUNEL positive cells was seen in Ad/GFP and PBS treated tumors with a significant enhancement in the number of TUNEL positive or apoptotic cells seen in -overexpressing tumors.

We also tried LNCaP cells in nude mice, but, in contrast to Du145 cells, LNCaP cells did not generate enough large tumors even 5 weeks after injection of cells to do a complete experiment. However, in a limited number of tumors, we observed similar results with Ad/ KChAP injection. Overexpressed KChAP shrunk LNCaP tumors to half their original size while Ad/GFP or PBS treated tumors tripled tumor volume in a 5 week period (data not shown). Immunohistological examination of LNCaP-derived tumor sections showed 088 antibody positive staining which correlated with increased apoptosis and TUNEL positive cells (data not shown). The results indicate that overexpression of KChAP in LNCaP and Du145 prostate cancer cells produces apoptosis and direct injection of Ad/KChAP into xenografts of LNCaP and Du145 tumors in nude mice suppresses tumor growth.

#### EXAMPLE 4: Inducing Apoptosis in Breast Cancer Cells by Increasing Intracellular Levels of KChAP

Cells from the mammary carcinoma cell line MCF-7 were infected with either Ad/GFP or Ad/ KChAP as described above in Example 1. Three days post infection the cells were assayed for PARP cleavage as described above. The results demonstrated the overexpression of KChAP in mammary epithelial cancer cells induces apoptosis.

#### EXAMPLE 5 Detection of Cancer Cells with Anti-KChAP Anti- Antibodies

Proteins were extracted from a liver cancer cell line (HumI), colorectal cancer tissue and nearby normal tissue, and brain tumor tissue and nearby normal tissue. Extracted proteins were separated by 6-15% SDS-PAGE, and assayed on a Western blot by reacting



with antibody 899. As shown in Figure 11, the extracts obtained from the liver cell line, the colorectal cancer tissue and brain tumor tissue contained higher levels of than extracts obtained from normal cell lines, normal colorectal tissue, and normal brain tissue respectively. These results demonstrate that intracellular levels of KChAP can be used as a diagnostic marker for liver cancer, colorectal cancer and brain cancer and that a method which employs anti-KChAP antibodies to assess intracellular levels of KChAP can be used to detect liver cancer cells, colorectal cancer cells and brain cancer cells in a tissue sample obtained from a patient.

## CLAIMS

What is claimed is:

1. A method for inducing apoptosis in hyperproliferative human cells comprising: increasing the level in the cells of at least one potassium channel modulatory protein selected  
5 from the group consisting of human KChAP protein, a biologically active variant of human KChAP protein, and a biologically active KChAP related protein.
2. The method of claim 1 wherein levels of said protein in the cells is increased by contacting the cells with at least one protein selected from the group consisting of human  
10 KChAP protein, a biologically active variant of KChAP protein, and a biologically active KChAP related protein under conditions which permit uptake of said protein.
3. The method of claim 1 wherein levels of said protein is increased in said cells by contacting said cells with a nucleic acid encoding at least one potassium channel modulatory  
15 protein under conditions permitting uptake of said nucleic acid by the cell, said nucleic acid comprising:
  - i) a sequence encoding native KChAP protein, a biologically active variant of KChAP protein, or a biologically active KChAP related protein, and
  - ii) a promoter active in the cancer cell, wherein the promoter is operably linked to  
20 the sequence encoding said protein.
4. A method for inducing apoptosis in human cancer cells comprising: increasing the level in the cells of at least one potassium channel modulatory protein selected  
25 from the group consisting of human KChAP protein and a biologically active variant of human KChAP protein.
5. The method of claim 4 wherein levels of said protein in the cancer cells is increased by contacting the cancer cells with at least one protein selected from the group consisting of  
30 human KChAP protein, and a biologically active variant of KChAP protein.
6. The method of claim 4 wherein levels of said protein is increased in the cancer cells by contacting the cancer cells with a nucleic acid encoding at least one potassium channel

modulatory protein under conditions permitting uptake of said nucleic acid by the cell, said nucleic acid comprising:

- i) a sequence encoding human KChAP protein and a biologically active variant of KChAP protein; and
  - ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the sequence encoding said protein.
- 5
7. The method of claim 4 wherein the cancer cells comprise a native p53 protein.
  8. The method of claim 4 wherein the cancer cells comprise a mutant p53 protein.
  9. The method of claim 5 wherein the cancer cells are in a tumor in a subject, and wherein the protein is administered to the subject by intratumoral or intralesional injection.
  10. The method of claim 6 wherein the cancer cells are in a tumor in a subject, and wherein the nucleic acid is administered to the subject by intratumoral or intralesional injection.
  11. A method of treating a subject with a hyperproliferative disorder comprising:
    - administering a pharmaceutical composition to said subject, said pharmaceutical composition comprising at least one agent selected from the group consisting of:
      - a) at least one potassium channel modulatory protein selected from the group consisting of human KChAP protein, a biologically active variant of human KChAP protein, and a biologically active KChAP related protein; and
      - b) a nucleic acid encoding at least one potassium channel modulatory protein, comprising:
        - i) a sequence encoding human KChAP protein, a biologically active variant of human KChAP protein, or a biologically active KChAP related protein, and
        - ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the sequence encoding said protein.
- 10
- 15
- 20
- 25
- 30

12. The method of claim 11 wherein the hyperproliferative disorder is a cancer.

13. The method of claim 11 wherein the hyperproliferative disorder is an epithelial carcinoma, a lymphoma, or a leukemia.

5

14. The method of claim 11 wherein the hyperproliferative disorder is prostate cancer.

15. The method of claim 12 wherein the pharmaceutical composition comprises a nucleic acid comprising a sequence encoding human KChAP protein or a biologically active variant of human KChAP protein, wherein said variant comprises a sequence which is at least 90% identical to human KChAP protein and has the ability to induce apoptosis in the cells of said cancer.

16. The method of claim 12 wherein the active agent is a human KChAP protein or a biologically active variant of human KChAP protein, wherein said variant comprises a sequence which is at least 90% identical to human KChAP protein and has the ability to induce apoptosis in the cells of said cancer.

17. The method of claim 12 wherein the active agent is a nucleic acid which is in a vector or associated with a liposome.

18. The method of claim 17 wherein the pharmaceutical composition is administered by intratumoral or intralesional injection.

19. The method of claim 12 wherein the active agent is a protein and the pharmaceutical composition is administered by intratumoral or intralesional injection.

20. A method of detecting cancer cells in a test sample, said sample comprising cells selected from the group consisting of liver tissue cells, brain tissue cells, colon tissue cells, and rectal tissue cells, said method comprising:

assaying for an increase in the intracellular levels of KChAP protein or a KChAP mRNA in said test sample.

21. The method of claim 20 wherein the method comprises:

a) contacting said cells or a protein extract therefrom with anti-KChAP antibodies under conditions wherein binding said antibodies to KChAP protein occurs ; and

5 b) assaying for a complex between said antibodies and a protein in said cells or said extract,


wherein an increase in the level of the antigen-antibody complexes in the cells or protein extract of said test sample as compared to the level of the antigen-antibody complexes in the cells or protein extract of a corresponding control sample, indicates that the test sample  
10 contains or was derived from cancerous cells.

22. The method of claim 20 wherein the method comprises assaying for KChAP mRNA in said sample, wherein an increase in the level of KChAP mRNA in said test sample as compared to the level of KChAP mRNA in a corresponding control sample, indicates that the test sample contains or was derived from cancerous cells.

15 23. A method of inhibiting cell cycling in cancer cells that contain a wild-type p53 protein, comprising: contacting the cancer cells with a nucleic acid encoding at least one potassium channel modulatory under conditions permitting uptake of said nucleic acid by the cell, said nucleic acid comprising:

20 i) a sequence encoding human KChAP protein and a biologically active variant of KChAP protein; and

ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the sequence encoding said protein.








Fig. 2



Ad/LacZ

Infection	% Comet Pos. cells	# cells scored
1	1.1	186
2	1.3	234
3	0.9	347
4	0	279



Ad/KChAP

Infection	% Comet Pos. cells	# cells scored
1	30.3	145
2	27.0	148
3	22.4	170
4	17.7	175

Ad/LacZ Ad/KChAP



KChAP, 088 antibody



PARP

B.

A.

Fig. 3




**A**

**Ad/LacZ Ad/KChAP**



**KChAP, 088**



**PARP**



**p53, total**



**p53, phospho-ser15**



**STAT3**



**STAT1**



**Actin**

**B**

**Std medium**

g k g k g k g k

**Extracellular  
K<sup>+</sup>, mM**

**5 25 50**

g k g k g k g k



**PARP**



**KChAP**



**p53-phosphoser15**



**total p53**



**STAT3**

*Fig. 4*





Fig. 5

A



B





Fig. 6



*Fig. 7*




Fig. 8

A  
P  
a  
I

1 atgaagatcaaagagctttaccgaacgacgctttccccggaagaccctggggccctctgat 60  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 M K I K E L Y R R R F P R K T L G P S D -

61 ctctcccttctctctttgccccctggcacctctcctgtaggctcccctggcctctctagct 120  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 L S L L S L P P G T S P V G S P G P L A -

A  
P  
a  
I

121 cccattcccccaacgctgttggccccctggcacccctgctgggcccccaagcgtgaggtggac 180  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 P I P P T L L A P G T L L G P K R E V D -

181 atgcacccccctctgccccagcctgtgcaccctgatgtcaccatgaaaccattgccccttc 240  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 M H P P L P Q P V H P D V T M K P L P F -

241 tatgaagtctatggggagctcatccggcccaccacccttgcacccacttctagccagcgg 300  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 Y E V Y G E L I R P T T L A S T S S Q R -

301 tttgaggaagcgcactttacctttgcccctcacaccccagcaagtgcagcagattcttaca 360  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 F E E A H F T F A L T P Q Q V Q Q I L T -

361 tccagagaggttctgccaggagccaaatgtgattataccatacaggtgcagctaagggttc 420  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 S R E V L P G A K C D Y T I Q V Q L R F -

P  
V  
U  
I  
I

Fig. 9

```

tgtctctgtgagaccagctgccccaggaagattatccccccaacctcttgtcaag
421 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
C L C E T S C P Q E D Y F P P N L F V K -
      B
      s
      t
      E
      I
      I

gttaatgggaaactgtgccccctgcccgggttaccttcccccaaccaagaatggggccgag
481 -----+-----+-----+-----+-----+-----+-----+-----+ 540
V N G K L C P L P G Y L P P T K N G A E -
ccaagaggcccagccgccccatcaacatcacaccctggctcgactctcagccaactggt
541 -----+-----+-----+-----+-----+-----+-----+-----+ 600
P K R P S R P I N I T P L A R L S A T V -
ccaacaccattgtggtcaattggtcatctgagttcggacggaattactccttgtctgtg
601 -----+-----+-----+-----+-----+-----+-----+-----+ 660
P N T I V V N W S S E F G R N Y S L S V -
      B
      s
      a
      W
      I
      I

tacctggtgaggcagttgactgcaggaacccttctacaaaaactcagagcaaagggtatc
661 -----+-----+-----+-----+-----+-----+-----+-----+ 720
Y L V R Q L T A G T L L Q K L R A K G I -
cgaaccagaccactcgccggcactgatcaaggagaaattgactgctgacccctgacagt
721 -----+-----+-----+-----+-----+-----+-----+-----+ 780
R N P D H S R A L I K E K L T A D P D S -
gaggtggccactacaagtctccgggtgtcactcatgtgcccgctaggaagatgcccctg
781 -----+-----+-----+-----+-----+-----+-----+-----+ 840
E V A T T S L R V S L M C P L G K M R L -
      P
      s
      t
      I

actgtcccttgtcgtgcctcacctgtgccacctgcagagcttcgatgctgcctttat
841 -----+-----+-----+-----+-----+-----+-----+-----+ 900
T V P C R A L T C A H L Q S F D A A L Y -
ctacagatgaatgagaagaagcctacatggacatgtcctgtgtgtgacaagaaggctccc
901 -----+-----+-----+-----+-----+-----+-----+-----+ 960

```

Fig. 9 (continued)

```

L Q M N E K K P T W T C P V C D K K A P -
tatgaatctcttatcattgatgggtttatttatggagattcttagttcctggtcagattgt
961-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1020
Y E S L I I D G L F M E I L S S C S D C -
                P      B
                f      a
                l      m
                M      H
                I      I
gatgagatccaattcatggaagatggatcctggtgcccaatgaaacccaagaaggaggca
1021-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1080
D E I Q F M E D G S W C P M K P K K E A -
                P
                f
                l
                M
                I
tctgaggtttgcccccgccagggtatgggctggatggcctccagtacagcccagtccag
1081-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1140
S E V C P P P G Y G L D G L Q Y S P V Q -
gggggagatccatcagagaataagaagaagggtcgaagttattgacttgacaatagaaagc
1141-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1200
G G D P S E N K K K V E V I D L T I E S -
                P
                V
                u
                I
                I
tcatcagatgaggaggatctgccccctaccaagaagcactgttctgtcacctcagctgcc
1201-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1260
S S D E E D L P P T K K H C S V T S A A -
atccccggcctacctggaagcaaaggagtcttgacatctggccaccagccatcctcggtg
1261-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1320
I P A L P G S K G V L T S G H Q P S S V -
ctaaggagccctgctatgggcacgttgggtggggatttctgtccagtctccactacat
1321-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1380
L R S P A M G T L G G D F L S S L P L H -
gagtaccacactgccttccaetgggagccgacatccaagggttagattttattttcattt
1381-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1440
E Y P P A F P L G A D I Q G L D L F S F -
cttcagacagagagtcagcactatggcccctctgtcatcacctcactagatgaacaggat

```

Fig. 9 (continued)



```

1441-----+-----+-----+-----+-----+-----+-----+ 1500
      L Q T E S Q H Y G P S V I T S L D E Q D -
                                     A
                                     P
                                     a
                                     I
      gcccttggccacttcttccagtagcgaggacccttctcactttctgggcccactggcc
1501-----+-----+-----+-----+-----+-----+-----+ 1560
      A L G H F F Q Y R G T P S H F L G P L A -
                                     P           N
                                     s           a
                                     t           r
                                     I           I
      cccacgctggggagctcccactgcagcgccactccggcgccccctcctggccgtgtcagc
1561-----+-----+-----+-----+-----+-----+-----+ 1620
      P T L G S S H C S A T P A P P P G R V S -
                                     S
                                     a
                                     u
                                     I
      agcattgtggcccctgggggggccccttgagggaggggcatggaggaccctgccctcaggt
1621-----+-----+-----+-----+-----+-----+-----+ 1680
      S I V A P G G A L R E G H G G P L P S G -
      ccctctttgactggctgtcggtcagacatcatttccctggactga
1681-----+-----+-----+-----+-----+-----+-----+ 1725
      P S L T G C R S D I I S L D * -
  
```

Enzymes that do cut:

ApaI    BamHI    BsaWI    BstEII    NarI    PflMI    PstI    PvuII  
 SauI

Enzymes that do not cut:

AatII    AgeI    AseI    AvaI    BbrPI    BfrI    BglII    BsaBI  
 BsmI    BssHII    BstBI    BstXI    ClaI    DraI    DraIII    EagI  
 EcoRI    HindIII    HpaI    KpnI    MluI    NcoI    NdeI    NheI  
 NotI    NruI    NsiI    PmlI    PvuI    SacII    SalI    ScaI  
 SfiI    SmaI    SnaBI    SpeI    SspI    StuI    XbaI    XhoI

Fig. 9 (continued)

NP1ASH	MADJALAKOMANIL	KUPEL... ..	82
NP1ASH	... ..	... ..	83
NP1ASH	... ..	... ..	75
NP1ASH	... ..	... ..	89
NP1ASH	... ..	... ..	88
NP1ASH	... ..	... ..	81
NP1ASH	... ..	... ..	169
NP1ASH	... ..	... ..	166
NP1ASH	... ..	... ..	116
NP1ASH	... ..	... ..	179
NP1ASH	... ..	... ..	179
NP1ASH	... ..	... ..	164
NP1ASH	... ..	... ..	259
NP1ASH	... ..	... ..	258
NP1ASH	... ..	... ..	259
NP1ASH	... ..	... ..	269
NP1ASH	... ..	... ..	251
NP1ASH	... ..	... ..	343
NP1ASH	... ..	... ..	344
NP1ASH	... ..	... ..	291
NP1ASH	... ..	... ..	355
NP1ASH	... ..	... ..	355
NP1ASH	... ..	... ..	335
NP1ASH	... ..	... ..	425
NP1ASH	... ..	... ..	426
NP1ASH	... ..	... ..	373
NP1ASH	... ..	... ..	437
NP1ASH	... ..	... ..	437
NP1ASH	... ..	... ..	425
NP1ASH	... ..	... ..	493
NP1ASH	... ..	... ..	494
NP1ASH	... ..	... ..	438
NP1ASH	... ..	... ..	503
NP1ASH	... ..	... ..	503
NP1ASH	... ..	... ..	510
NP1ASH	... ..	... ..	579
NP1ASH	... ..	... ..	580
NP1ASH	... ..	... ..	515
NP1ASH	... ..	... ..	550
NP1ASH	... ..	... ..	563
NP1ASH	... ..	... ..	650
NP1ASH	... ..	... ..	651
NP1ASH	... ..	... ..	583
NP1ASH	... ..	... ..	572
NP1ASH	... ..	... ..	621

Fig 10

# KChAP expression in Human Brain Tumors and Colon Cancers

C#64 C#65

Huml N T N T 46 54 61 64 71 85 86




Fig 11